Personalis Reports Q4/FY25 Results, Secures Medicare Coverage, Projects 5x Clinical Revenue Growth in 2026

summarizeSummary

Personalis, Inc. announced Q4 and full-year 2025 financial results, highlighted by a 400% increase in clinical test volume, secured Medicare coverage for breast and lung cancer surveillance, and projected a five-fold increase in clinical revenue for 2026.

check_boxKey Events

• Strong Clinical Growth

  Clinical test volume surged 400% in 2025 to 16,233 tests, with Q4 volume up 41% sequentially over Q3 2025.

• Pivotal Medicare Coverage Secured

  Received Medicare coverage approval for breast and lung cancer recurrence surveillance, expected to be a key catalyst for clinical revenue generation.

• Positive 2026 Outlook

  Projected 2026 total revenue of $78.0 to $80.0 million, with clinical revenue expected to grow approximately five-fold to $10.0 to $11.0 million.

• Fortified Balance Sheet

  Ended 2025 with approximately $240 million in cash, cash equivalents, and short-term investments, including $109 million in net proceeds from an At-The-Market (ATM) sales program.

auto_awesomeAnalysis

This 8-K provides final Q4 and full-year 2025 financial results, confirming the preliminary announcement from January 8, 2026, and crucially offers detailed 2026 financial guidance. The most significant positive developments are the successful securing of Medicare coverage for breast and lung cancer surveillance, which is a major catalyst for future clinical revenue, and the projected five-fold increase in clinical revenue for 2026. While overall 2025 revenue declined and the company anticipates continued significant net losses and cash usage in 2026, the strategic progress in its core precision oncology business, particularly in minimal residual disease (MRD) testing, is substantial. The company's strong cash position, partly bolstered by a recent At-The-Market (ATM) program, provides the necessary capital to fund this commercial expansion. Investors should monitor the execution of the 'Win-in-MRD' strategy and the actual realization of the projected clinical revenue growth and Medicare reimbursement.